Table 1.

Baseline characteristics of pancreatic neuroendocrine neoplasm patients.

Characteristics	All patients (n = 174)
Gender, n (%)
Male	82 (47.1)
Female	92 (52.9)
Age, years (median, IQR)	53 (43–61)
Functionality, n (%)
Nonfunctional	139 (79.9)
Functional	35 (20.1)
Insulinoma	32 (18.4)
Glucagonoma	2 (1.1)
Somatostatinoma	1 (0.6)
Tumor location, n (%)
Head/neck	70 (40.2)
Body/tail	103 (59.2)
Multiple parts	1 (0.6)
Tumor size, cm (median, IQR)	2.7 (1.5–4.0)
Tumor focality, n (%)
Single	167 (96.0)
Multiple	7 (4.0)
Necrosis, n (%)
Yes	8 (4.6)
No	166 (95.4)
Nerve invasion, n (%)
Yes	26 (14.9)
No	148 (85.1)
Vascular invasion, n (%)
Yes	28 (16.1)
No	146 (83.9)
Lymph node metastases, n (%)
Yes	15 (8.6)
No	159 (91.4)
WHO grade, n (%)
G1	73 (42.0)
G2	88 (50.6)
G3	13 (7.4)
TNM stage, n (%)
I	54 (31.0)
II	96 (55.2)
III	15 (8.6)
IV	9 (5.2)
Synchronous liver metastases, n (%)
Yes	9 (5.2)
No	165 (94.8)
Relapse, n (%)
Yes	24 (13.8)
No	142 (81.6)
Unknown	8 (4.6)
Death, n (%)
Yes	8 (4.6)
No	152 (87.4)
Unknown	14 (8.0)
Platelet count, ×109/L (median, IQR)	205 (167–244)
Neutrophil count, ×109/L (median, IQR)	3.3 (2.5–4.1)
Lymphocyte count, ×109/L (median, IQR)	1.9 (1.6–2.4)
Lymphocyte count, ×109/L (n, %)
≤1.4	30 (17.2)
>1.4	144 (82.8)
Monocyte count, ×109/L (median, IQR)	0.38 (0.31–0.49)
Platelet-to-lymphocyte ratio (median, IQR)	104 (89–131)
Neutrophil-to-lymphocyte ratio (median, IQR)	1.6 (1.3–2.2)
Neutrophil-to-lymphocyte ratio, n (%)
≤1.9	115 (66.1)
>1.9	59 (33.9)
Lymphocyte-to-monocyte ratio (median, IQR)	5.0 (3.9–6.5)
Lymphocyte-to-monocyte ratio, n (%)
≤5.0	90 (51.7)
>5.0	84 (48.3)
Systemic immune-inflammation index (median, IQR)	342 (241–452)

IQR, interquartile range; WHO, World Health Organization.